## Antimicrobial Therapy for Intra-Abdominal Infections
(NB Provincial Health Authorities Anti-Infective Stewardship Committee, November 2015)

<table>
<thead>
<tr>
<th>Origin/Severity of Intra-Abdominal Infection</th>
<th>Probable Pathogens</th>
<th>Preferred Empiric Regimens</th>
<th>Alternative Empiric Regimens</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Community Acquired Infection, Mild to Moderate severity:</strong>&lt;br&gt;i.e. gastroduodenal perforation, cholangitis, cholecystitis, appendicitis, diverticulitis, primary (spontaneous) bacterial peritonitis&lt;br&gt;With no evidence of systemic toxicity (APACHE II score less than 15)</td>
<td>Core: Enterobacteriaceae (i.e. <em>E. coli</em>, <em>Klebsiella</em> spp, <em>Proteus</em> spp, <em>Enterobacter</em> spp., <em>Anaerobacter</em> spp., <em>B. fragilis</em>, <em>Clostridium</em> spp., etc...), <em>Streptococcus</em> spp, ± <em>Enterococcus</em> spp (see below if isolated)</td>
<td>ceFAZolin 2 g IV q8h* + metroNIDAZOLE 500 mg IV/PO q12h*&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>CefOXitin 2 g IV q6h*&lt;sup&gt;a&lt;/sup&gt; OR gentamicin 5 – 7 mg/kg IV q24h* + metroNIDAZOLE 500 mg IV/PO q12h</td>
<td><strong>Duration of Therapy, dependent on clinical picture:</strong>&lt;br&gt;○ 5 – 7 days usually sufficient if optimal source control obtained&lt;br&gt;○ If intra-abdominal abscess: antimicrobial therapy may be prolonged, with duration dependant on resolution (up to 4 to 6 weeks)&lt;br&gt;○ Day of intervention (drainage, surgery, etc.) considered as day 1 of therapy&lt;br&gt;&lt;br&gt;<strong>Intravenous-to-Oral Conversion:</strong>&lt;br&gt;: amoxicillin/clavulanate 875/125 mg po q12h*&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Community Acquired Infection, Severe:</strong>&lt;br&gt;As above with APACHE II score greater than or equal to 15, signs of systemic toxicity, greater than 70 years old, immunocompromised, secondary peritonitis, cancer, poor nutritional status or incomplete or delayed source control</td>
<td>Core</td>
<td>cefTRIAXone 2 g IV q24h* + metroNIDAZOLE 500 mg IV/PO q12h</td>
<td>piperacillin/tazobactam 3.375 g IV q6h*&lt;sup&gt;d,e,h&lt;/sup&gt;</td>
<td><strong>Intravenous-to-Oral Conversion:</strong>&lt;br&gt;: As for mild to moderate above</td>
</tr>
<tr>
<td><strong>Healthcare Associated</strong>&lt;br&gt;Hospitalized greater than 48 hours at time of onset, recent prolonged hospitalization, post-operative infection, long term care, rehab, dialysis, nursing home, recent antibiotics</td>
<td>Core Plus: Pseudomonas, Multidrug Resistant (MDR) Gram-negative bacteria, MRSA (see below if isolated)</td>
<td>piperacillin/tazobactam 3.375 g IV q6h&lt;sup&gt;d,e,h&lt;/sup&gt;</td>
<td>imipenem-cilastin 500 mg IV q6h*&lt;sup&gt;a&lt;/sup&gt; (preferred if suspected MDR Gram-negative)</td>
<td><strong>Intravenous-to-Oral Conversion:</strong>&lt;br&gt;: Ciprofloxacin 400 mg IV q12h* + vancomycin 15 mg /kg IV q12h&lt;sup&gt;*a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

(continued on next page)
<table>
<thead>
<tr>
<th>Origin/Severity of Intra-Abdominal Infection</th>
<th>Probable Pathogens</th>
<th>Preferred Directed Regimens</th>
<th>Alternative Directed Regimens</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>If MRSA Suspected (colonized or history of MRSA infection)</td>
<td></td>
<td>Add vancomycin 15 mg/kg IV q12h* (for target trough of 15 – 20 mg/L)</td>
<td></td>
<td>micafungin preferred if Candida krusei or Candida glabrata isolated</td>
</tr>
<tr>
<td>If Candida isolated</td>
<td></td>
<td>Add fluconazole 800 mg IV/PO then 400 mg IV/PO q24h*</td>
<td>micafungin 100 mg IV q24h</td>
<td>Enterococcal coverage only necessary if: Ø isolated as predominant organism in culture OR Ø healthcare associated infection OR Ø patient is immunocompromised OR Ø Blood culture positive</td>
</tr>
<tr>
<td>If Enterococci isolated</td>
<td></td>
<td>Add ampicillin 2 g IV q6h* (not required if on piperacillin/tazobactam or imipenem-cilastin)</td>
<td>Immediate (IgE-mediated) penicillin allergy or penicillin resistant: vancomycin 15 mg/kg IV q12h*</td>
<td>If Enterococcus faecium isolated and criteria for treatment met, use vancomycin as empiric therapy and reassess based on susceptibility results</td>
</tr>
</tbody>
</table>

**Clinical Pearls:**
- Antimicrobial therapy does not preclude source control (ex. percutaneous drainage or surgery)
- Patients with recent prolonged hospitalization (5 or more days) or recent antimicrobials (2 or more days) within the previous 3 months pose risk for resistance and treatment failure, treat as healthcare associated
- Empiric Enterococci coverage is not recommended for mild-moderate severity community-acquired intra-abdominal infections. It should be reserved for patients in whom this pathogen is more frequently found (healthcare-associated infections, particularly those with postoperative infection, presence of severe immunosuppression, recurrent infection, patients who receive long-term cephalosporin treatment, and those with valvular heart disease or prosthetic intravascular materials)
- CAUTION: Significant E.coli resistance (greater than 20%) to fluoroquinolones and amoxicillin exist in some areas of the province; check local antibiogram and confirm C&S results when available
- Pathogen directed therapy should be used when culture and susceptibility results are available

**Workup:**
- Recommend blood, intraoperative and/or abscess fluid cultures in patients with post-operative or healthcare-associated infections; those with treatment failure and/or requiring re-operation; or recently on antimicrobial therapy
- Blood cultures recommended if patient has sepsis syndrome
- Reassess initial empiric therapy based on clinical state & results of microbiological analysis
- Anaerobic coverage not indicated for cholecystitis & cholangitis unless biliary-enteric anastomosis is present or aggravating factors (advanced age, immunosuppression or metabolic instability)
- Most cases of diverticulitis can be managed with oral antibiotic therapy
- Intravenous-to-Oral conversion: consider if infection well controlled, afebrile x 24 hrs., hemodynamically stable, tolerating oral intake and no clinical, radiographic or surgical sign of intra-abdominal collection from non-optimal drainage
- For Pseudomonas aeruginosa infection, piperacillin/tazobactam dosage may be increased to 4.5 gm IV q6h
- Anaerobic coverage adequate, addition of metronIDAZOLE or clindamycin to piperacillin/tazobactam or imipenem-cilastin not necessary
- Adjust vancomycin dose to target a trough level of 10 to 20 mg/L
- Appropriate therapy option for patients with an immediate Type-1 (IgE-mediated) hypersensitivity reaction to penicillin (i.e. anaphylaxis, angioedema, laryngeal edema, urticaria)
- Avoid in patients with immediate Type-1 (IgE-mediated) hypersensitivity reaction to penicillin, significant risk of cross-reactivity exists.
- *Dose adjustment required in renal impairment
References: